首页 | 本学科首页   官方微博 | 高级检索  
   检索      

孟鲁司特钠联合布地奈德混悬液对哮喘急性发作患儿血清EOS、ECP水平和肺功能的影响
引用本文:阳 进,王瀚仪,肖 玲,王 俭,胡 兰,阳 梅.孟鲁司特钠联合布地奈德混悬液对哮喘急性发作患儿血清EOS、ECP水平和肺功能的影响[J].现代生物医学进展,2018(12):2392-2395.
作者姓名:阳 进  王瀚仪  肖 玲  王 俭  胡 兰  阳 梅
作者单位:眉山市人民医院儿内科;眉山市人民医院骨外科;眉山市妇幼保健院儿科
摘    要:目的:探索孟鲁司特钠联合布地奈德混悬液对哮喘急性发作患儿血清嗜酸性粒细胞(EOS)、嗜酸性粒细胞阳离子蛋白(ECP)水平和肺功能的影响。方法:选择自2015年10月至2016年10月我院收治的200例支气管哮喘急性发作患儿,按照随机数表法分成观察组和对照组各100例。对照组患儿口服孟鲁司特钠,观察组患儿在对照组基础上给予布地奈德气雾剂进行雾化治疗,两组均治疗1周。统计分析两组患儿的临床有效率,肺功能指标,包括第1秒用力呼气容积(FEV1)、用力肺活量(FVC)及FEV1/FVC,对比治疗前后两组患儿血清中EOS、ECP水平的变化。结果:治疗后,观察组的总有效率为97.00%,显著高于对照组的81.00%(P0.05);经治疗后两组患儿肺功能指标均较治疗前明显改善,且观察组患儿优于对照组(P0.05);两组患儿治疗后EOS、ECP水平均低于治疗前,而观察组患儿低于对照组,差异均有统计学意义(P0.05)。结论:孟鲁司特钠联合布地奈德对于小儿哮喘的急性发作具有良好的临床疗效,能显著改善患儿肺功能和血清中炎症因子的水平,减轻患儿体内的炎症反应,值得在临床上推广应用。

关 键 词:孟鲁司特钠  布地奈德  儿童  哮喘  急性发作  EOS  ECP
收稿时间:2017/8/5 0:00:00
修稿时间:2017/8/31 0:00:00

Effect of Montelukast Sodium Combined With Budesonide Inhalation Suspension on Serum EOS,ECP and Lung Function in Children with Acute Episoded Asthma
Abstract:ABSTRACT Objective: To explore the effect of montelukast sodium combined with budesonide inhalation suspension on serum eosinophilic cell(EOS), eosinophile cationic protein(ECP)and lung function in children with acute episoded asthma. Methods: Selected 200 children with acute episoded asthma who were treated in our hospital from October 2015 to October 2016, they were divided into control group and observation group according to the random number table method, with 100 patients in each group. Patients in control group were treated with montelukast sodium, while patients in observation group were treated with montelukast sodium combined with budesonide inhalation suspension, the treatment course of two groups was 1week. Statistically analyzed the clinical efficacy, pulmonary function, which including forced expiratory volume in the first second(FEV1), forced vital capacity(FVC)and FEV1/FVC, and the changes of serum EOS, ECP levels in two groups before and after treatment. Results: The total effective rate in observation group was 97%, which was significantly higher than control group(P<0.05). The pulmonary function indexes of two groups after treatment were sig- nificantly improved than before treatment, and the observation group were significantly better than control group(P<0.05). The serum EOS and ECP levels in two groups after treatment were significantly improved than before treatment, and the observation groups were significantly lower than control group, the differences were statistically significant(P<0.05). Conclusion: Montelukast sodium combined with budesonide inhalation suspension has a good clinical effect in treatment for children with acute asthma, which can significantly im- prove the pulmonary function and reduce the serum EOS, ECP levels, so as to relieve the inflammatory reaction of children, it is worth popularizing in clinical application.
Keywords:Montelukast sodium  Budesonide  Children  Asthma  Acute episoded  EOS  ECP
本文献已被 CNKI 等数据库收录!
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号